Halofuginone reduces the inflammatory responses of DSS-induced colitis through metabolic reprogramming

Keyphrases

• Inflammatory Response 100%
• Halofuginone 100%
• Metabolic Reprogramming 100%
• Dextran Sulfate Sodium-induced Colitis 100%
• L-carnitine 57%
• Colon Tissue 57%
• Hypoxia-inducible factor-1α (HIF-1α) 42%
• Spleen Tissue 28%
• Fatty Acid Oxidation 28%
• Liver Tissue 28%
• Metabolic Signature 28%
• Hypoxia 14%
• Inflammation 14%
• Inflammatory Cytokines 14%
• Tumor Necrosis Factor-α 14%
• Myeloperoxidase Activity 14%
• Metabolism 14%
• Metabolic Profiling 14%
• Mass Spectrometry-based Metabolomics 14%
• Dextran Sulfate Sodium 14%
• Anti-inflammatory Effect 14%
• Inflammatory Bowel Disease 14%
• Colon 14%
• Genome Analysis 14%
• Small Metabolites 14%
• Colitis 14%
• Colonic Lesions 14%
• Disease Activity Score 14%
• Palmitoyl-CoA 14%
• Antiparasitic Drugs 14%
• Isobutyrylcarnitine 14%

Biochemistry, Genetics and Molecular Biology

• Dextran 100%
• Reprogramming 100%
• Sodium Sulfate 100%
• Colon 100%
• Hypoxia Inducible Factor 1alpha 60%
• Beta Oxidation 40%
• Mass Spectrometry 20%
• Metabolite 20%
• Metabolic Pathway 20%
• Metabolomics 20%
• Tumor Necrosis Factor 20%
• Antiinflammatory Activity 20%
• Myeloperoxidase 20%
• Proinflammatory Cytokine 20%
• Tumor Necrosis Factor Alpha 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammation 100%
• Halofuginone 100%
• Dextran Sulfate Sodium-Induced Colitis 100%
• Acylcarnitine 42%
• Hypoxia Inducible Factor 1alpha 42%
• Fatty Acid 28%
• Cytokine 14%
• Tumor Necrosis Factor 14%
• Myeloperoxidase 14%
• Hypoxia 14%
• Antiinflammatory Activity 14%
• Colitis 14%
• Inflammatory Bowel Disease 14%
• Dextran Sulfate 14%
• Antiparasitic Agent 14%
• Disease Activity 14%
• Palmitoylcarnitine 14%